The global antibiotic-resistant infections treatment market is poised for substantial growth, with market value expected to surge from USD 4,377.4 million in 2024 to an impressive USD 7,637.5 million by 2034, achieving a compound annual growth rate (CAGR) of 5.7% during the assessment period.
Antibiotic-resistant infections, often referred to as “superbugs,” pose a significant global health challenge, driving innovation and investment in novel treatment solutions. The increasing prevalence of resistant pathogens, coupled with heightened awareness among healthcare providers, is fueling market expansion.
Unveil Market Trends: Get Your Sample Report Now! https://www.futuremarketinsights.com/report-sample#5245502d47422d3139373335
Key factors contributing to this robust growth include:
- Advancements in Drug Development: The emergence of innovative antibiotics and alternative therapies designed to combat resistant strains.
- Rising Healthcare Investments: Governments and private sectors worldwide are prioritizing initiatives to combat antimicrobial resistance (AMR).
- Collaborative Research Efforts: Enhanced collaboration between pharmaceutical companies, research institutions, and regulatory bodies to accelerate drug approvals.
The demand for effective treatments is especially acute in regions with high infection rates and limited access to adequate healthcare facilities. Market players are focusing on expanding their portfolios to address unmet clinical needs, offering a wide range of therapies, including combination drugs, monoclonal antibodies, and phage therapy.
As the market evolves, stakeholders are urged to align with sustainable practices to ensure the longevity of antibiotic efficacy while advancing patient care.
Key Takeaways from the Market Study
- By drug class, the Nirtofurans (Nitrofurantoin) will hold a lucrative share value of 4% in 2024.
- By route of administration, oral segment will hold the highest segment share in terms of the market share value of 0% in 2024.
- By disease indication, the cystitis segment will hold a lucrative share value of 9% in 2024, among other disease indications.
- By age group, the adult segment will contribute a lucrative share value of 2% in 2024.
- By distribution channel, the retail pharmacies will hold a lucrative share value of 1% in 2024.
- South Asia & Pacific will be considered the leading region with a value share of 3% in 2024.
“Expanding indications and formulations in existing portfolios with combination products and increased expenditure and research funding is responsible for the growth of the market,” says an analyst of Future Market Insights.
Increased Market Attention: Delve into Detailed Trends and Analysis with Our Report! https://www.futuremarketinsights.com/reports/antibiotic-resistant-infections-treatment-market
Market Competition
Collaboration and expansion among the companies or brands is the key strategy of the leading manufacturers of the market such as Johnson & Johnson (Janssen Pharmaceuticals, Inc.) GlaxoSmithKline Plc (GSK), among others, to enhance their presence in the market and compete with other competitors during the coming years. Following are a few examples of key developments made by them to be at the top position:
- Johnson & Johnson have the J&J Centers for Global Health Discovery, a new global network of specially designed partnerships. The growth was intended to accelerate discovery research against emerging threats of TB, dengue fever, flavivirus, coronavirus, and antimicrobial resistance.
- GSK plc joined as a Founding Partner of the Fleming Initiative in May 2024. This initiative represents a collaborative approach to tackling the global challenge of antimicrobial resistance.
Leading Antibiotic-Resistant Infections Treatment Manufacturers:
- Pfizer Inc.
- Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
- Merck & Co., Inc.
- Glaxosmithkline Plc (GSK)
- F.Hoffmann-La Roche Ltd.
- AbbVie
- AstraZeneca
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Sandoz AG
- Lupin Ltd.
- Advacare Pharma
- Validus Pharmaceuticals LLC
Get Expert Healthcare Industry Insights Now! https://www.futuremarketinsights.com/industry-analysis/therapy-area
Key Segments of Market Report:
By Drug Class:
As per drug class, the market has been categorized into penicillin and combinations, (piperacillin and tazobactam, pivmecillinam, Ticarcillin/Clavulanate, amoxicillin and Clavulanate potassium), cephalosporin, Colistin, carbapenems, (meropenem and imipenem), fluoroquinolones, aminoglycoside antibiotics, amikacin, gentamicin, (Nitrofurans (nitrofurantoin), Fosfomycin) among others.
By Route of Administration:
This segment is further categorized into oral and parenteral.
By Disease Indication:
This disease indication segment is bifurcated into pyelonephritis or cUTI, cystitis, pneumonia among other disease indications.
By Age Group:
This age group segment is bifurcated into pediatric, adult, and geriatric.
By Distribution Channel:
Different distribution channels include hospital pharmacies, gynecology and urology clinics, drug stores, retail pharmacies, and online drug stores.
By Region:
Industry analysis has been carried out in key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East & Africa.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
